Press coverage about Atara Biotherapeutics (NASDAQ:ATRA) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Atara Biotherapeutics earned a media sentiment score of 0.24 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 45.8979034663777 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news articles that may have impacted Accern Sentiment Analysis’s scoring:
- ATARA Biotherapeutics (ATRA) Announces Positive Health Canada Regulatory Feedback for ATA129 (streetinsider.com)
- Atara Biotherapeutics Receives Positive Health Canada Regulatory Feedback for ATA129 (finance.yahoo.com)
- Atara Biotherapeutics, Inc. (ATRA) Given Average Rating of “Hold” by Brokerages (americanbankingnews.com)
- Atara Biotherapeutics, Inc. (ATRA) CEO Sells $66,088.00 in Stock (americanbankingnews.com)
- ATARA Biotherapeutics (ATRA) Announces FDA Orphan Drug Designation for ATA230 (streetinsider.com)
Atara Biotherapeutics (NASDAQ:ATRA) traded up 2.40% during midday trading on Tuesday, reaching $14.95. 90,900 shares of the company’s stock were exchanged. The firm has a 50-day moving average price of $14.74 and a 200 day moving average price of $15.88. Atara Biotherapeutics has a 12-month low of $11.80 and a 12-month high of $23.00. The company’s market cap is $456.86 million.
Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.94) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.89) by ($0.05). On average, analysts expect that Atara Biotherapeutics will post ($3.89) EPS for the current fiscal year.
ATRA has been the subject of several recent analyst reports. Jefferies Group LLC reiterated a “buy” rating and set a $30.00 price objective on shares of Atara Biotherapeutics in a research report on Thursday, June 22nd. Zacks Investment Research upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, June 27th. William Blair reiterated an “outperform” rating on shares of Atara Biotherapeutics in a research report on Monday, June 26th. ValuEngine upgraded shares of Atara Biotherapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Finally, BidaskClub cut shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 22nd. Four equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. Atara Biotherapeutics has an average rating of “Hold” and a consensus price target of $23.60.
In other Atara Biotherapeutics news, CEO Isaac E. Ciechanover sold 5,500 shares of the business’s stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $16.49, for a total transaction of $90,695.00. Following the transaction, the chief executive officer now directly owns 731,859 shares of the company’s stock, valued at approximately $12,068,354.91. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Isaac E. Ciechanover sold 4,400 shares of the business’s stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $15.02, for a total transaction of $66,088.00. Following the transaction, the chief executive officer now directly owns 737,767 shares in the company, valued at $11,081,260.34. The disclosure for this sale can be found here. Over the last three months, insiders have sold 49,509 shares of company stock worth $726,242. Insiders own 16.10% of the company’s stock.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.